In-Licensing

LipoNova AG aims to continually expand its product portfolio and build international partnerships. We constantly look to add value through the in-licensing of new complementary compounds.

Out-Licensing

LipoNova AG plans to bring Reniale® to the market on a named patient basis until it is approved and licensed. Named patient programmes are a legal and ethical way to respond to the demand for an unlicensed medicine to meet the special needs of individual patients when a suitable alternative does not exist.

For this purpose we are looking for sales partners with expertise in oncology, individualised drugs or rare diseases and contacts in renowned oncological centres.

For questions or further information contact:

Dr. Cornelius Sobel
Telephone: +49 (0) 511 540 99-124
mail: businessdevelopment@liponova.de

edited: 16.01.2008